MedTrace Logo

Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival Recession

NCT07763093 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-08-13

No results posted yet for this study

Summary

This randomized controlled clinical trial aims to compare the clinical effectiveness of the Vertically Coronally Advanced Flap (VCAF) and the Coronally Advanced Flap (CAF), both combined with connective tissue graft (CTG) and enamel matrix derivative (EMD), for the treatment of Miller Class I gingival recession. Twenty-six Miller Class I gingival recession defects will be randomly assigned in a 1:1 ratio to either the VCAF + CTG + EMD group or the CAF + CTG + EMD group. Clinical outcomes, including mean root coverage, complete root coverage, recession depth, recession width, probing depth, clinical attachment level, keratinized tissue width, gingival thickness, vestibular depth, and esthetic outcomes, will be assessed at baseline and throughout a 6-month follow-up period. Three-dimensional digital models obtained from an intraoral scanner will also be used to evaluate soft tissue changes following treatment. The study is designed to determine whether the VCAF technique provides superior clinical and esthetic outcomes compared with the conventional CAF technique.

Conditions

  • Gingival Recession

Interventions

PROCEDURE

Coronally Advanced Flap

A root coverage surgical procedure using the conventional Coronally Advanced Flap (CAF) in combination with a connective tissue graft and enamel matrix derivative for the treatment of Miller Class I gingival recession.

PROCEDURE

Vertically Coronally Advanced Flap

A root coverage surgical procedure using the Vertically Coronally Advanced Flap (VCAF) in combination with a connective tissue graft and enamel matrix derivative for the treatment of Miller Class I gingival recession.

Sponsors & Collaborators

  • University of Medicine and Pharmacy at Ho Chi Minh City

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2026-12-25
Completion
2026-12-25

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07763093 on ClinicalTrials.gov